These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 19855241)

  • 21. Evaluation of Epstein-Barr virus antibodies, anti-VCA avidity by immunofluorescence and immunoblot assays for assessment of Epstein-Barr virus immunologic state.
    Sener AG; Afsar I; Pinar E
    J Virol Methods; 2009 Aug; 159(2):300-2. PubMed ID: 19406156
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Building a better lymphoma vaccine.
    Ainsworth C
    Nature; 2018 Nov; 563(7731):S52-S54. PubMed ID: 30429570
    [No Abstract]   [Full Text] [Related]  

  • 23. Tight regulation of the Epstein-Barr virus setpoint: interindividual differences in Epstein-Barr virus DNA load are conserved after HIV infection.
    Piriou E; van Dort K; Otto S; van Oers MH; van Baarle D
    Clin Infect Dis; 2008 Jan; 46(2):313-6. PubMed ID: 18171268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical consequences of Epstein-Barr virus infection and possible control by an anti-viral vaccine.
    Epstein MA; Morgan AJ
    Clin Exp Immunol; 1983 Aug; 53(2):257-71. PubMed ID: 6309441
    [No Abstract]   [Full Text] [Related]  

  • 25. Epstein-Barr virus detection in non-Hodgkin's lymphoma of the oral cavity: an immunocytochemical and in situ hybridization study.
    Leong IT; Fernandes BJ; Mock D
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Aug; 92(2):184-93. PubMed ID: 11505266
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epstein-Barr virus infection.
    Cohen JI
    N Engl J Med; 2000 Aug; 343(7):481-92. PubMed ID: 10944566
    [No Abstract]   [Full Text] [Related]  

  • 27. Regulatory T cell activity in primary and persistent Epstein-Barr virus infection.
    Wingate PJ; McAulay KA; Anthony IC; Crawford DH
    J Med Virol; 2009 May; 81(5):870-7. PubMed ID: 19319950
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody responses to Epstein-Barr virus-encoded latent membrane protein-1 (LMP1) and expression of LMP1 in juvenile Hodgkin's disease.
    Meij P; Vervoort MB; Bloemena E; Schouten TE; Schwartz C; Grufferman S; Ambinder RF; Middeldorp JM
    J Med Virol; 2002 Nov; 68(3):370-7. PubMed ID: 12226824
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular evidence of ocular Epstein-Barr virus infection.
    Slobod KS; Sandlund JT; Spiegel PH; Haik B; Hurwitz JL; Conley ME; Bowman LC; Benaim E; Jenkins JJ; Stocks RM; Gan Y; Sixbey JW
    Clin Infect Dis; 2000 Jul; 31(1):184-8. PubMed ID: 10913420
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epstein-Barr virus (EBV) early-antigen antibodies and EBV DNA load in blood, in posttransplantation lymphoproliferative disease.
    Leruez-Ville M; Talbotec C; Iserin F; Salomon R; Lacaille F; Rouzioux C
    J Infect Dis; 2004 Oct; 190(8):1524-5; author reply 1525-6. PubMed ID: 15378447
    [No Abstract]   [Full Text] [Related]  

  • 31. [Epstein-Barr virus in Hodgkin's disease: the example of central Tunisia].
    Korbi S; Trimeche M; Sriha B; Yacoubi MT; Hmissa S; Mokni M; Delvenne P; Boniver J; Rammeh S
    Ann Pathol; 2002 Apr; 22(2):96-101. PubMed ID: 12124490
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Control of Epstein-Barr virus load and lymphoproliferative disease by maintenance of CD8+ T lymphocytes in the T lymphocyte-depleted graft after bone marrow transplantation.
    Torre-Cisneros J; Román J; Torres A; Herrera C; Caston JJ; Rivero A; Mingot E; Rojas R; Martín C; Martínez F; Gómez P
    J Infect Dis; 2004 Nov; 190(9):1596-9. PubMed ID: 15478063
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic evaluation of a new panel of assays for Epstein-Barr virus serology.
    Radtke M; Gärtner B; Franke D
    Clin Lab; 2007; 53(3-4):149-50. PubMed ID: 17447650
    [No Abstract]   [Full Text] [Related]  

  • 34. Quantitative Epstein-Barr virus (EBV) serology in lung transplant recipients with primary EBV infection and/or post-transplant lymphoproliferative disease.
    Verschuuren E; van der Bij W; de Boer W; Timens W; Middeldorp J; The TH
    J Med Virol; 2003 Feb; 69(2):258-66. PubMed ID: 12683416
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epstein-Barr virus and lymphoproliferative disorders after transplantation.
    Am J Transplant; 2004 Nov; 4 Suppl 10():59-65. PubMed ID: 15504214
    [No Abstract]   [Full Text] [Related]  

  • 36. Epstein-Barr virus: Trigger for autoimmunity?
    Kaminski HJ; Minarovits J
    Ann Neurol; 2010 Jun; 67(6):697-8. PubMed ID: 20517931
    [No Abstract]   [Full Text] [Related]  

  • 37. A shadow of Epstein-Barr virus in the pathogenesis of atopic diseases.
    Okudaira H; Shuto H; Shuto C; Chiba T; Akiyama H; Ohta I; Matsuzaki G
    Clin Exp Allergy; 2001 Jan; 31(1):18-24. PubMed ID: 11167946
    [No Abstract]   [Full Text] [Related]  

  • 38. Contribution of viral recombinants to the study of the immune response against the Epstein-Barr virus.
    Delecluse HJ; Feederle R; Behrends U; Mautner J
    Semin Cancer Biol; 2008 Dec; 18(6):409-15. PubMed ID: 18938248
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibodies for detecting EBV latent proteins.
    Rowe M; Mehl A
    Methods Mol Biol; 2001; 174():219-27. PubMed ID: 11357648
    [No Abstract]   [Full Text] [Related]  

  • 40. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
    Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y
    Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.